Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A synthetic small molecule dipeptide with the chemical formula C21H30ClN3O2 and a molecular weight of approximately 391.9 g/mol. It is an experimental compound, not approved for clinical use, and has been referenced in chemical and pharmaceutical databases as a dipeptide derivative. There is no evidence of clinical trials or approved indications for this compound, nor detailed information on its mechanism of action or therapeutic target[5][7][9]. Some patent literature suggests related compounds may have antifungal activity, but there is no direct evidence that this specific molecule has been developed for any disease[6][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 3-cyclohexyl-D-alanyl-N-(3-chlorobenzyl)-L-prolinamide.